Wani binciken da aka buga a kan layi a cikin Journal of the American Medical Association a ranar 21 ga Mayu ya nuna cewa gwaje-gwajen kwayoyin halitta da yawa na ciwon daji na huhu na iya taimakawa wajen zaɓar abubuwan da ba su dace ba don maganin da aka yi niyya. Idan aka kwatanta da marasa lafiya waɗanda ba su karɓi maganin da aka yi niyya ba, marasa lafiyar da suka karɓi maganin ciwon huhu na huhu za su sami tsawon lokacin rayuwa. Koyaya, ana buƙatar gwajin gwaji na asibiti don tabbatar da ko wannan dabarun jiyya na iya inganta rayuwar marasa lafiya.
The introduction of targeted therapy has changed the situation of lung cancer treatment by integrating tumo genotyping with treatment decisions. adenocarcinoma is the most common type of lung cancer; 130,000 people are diagnosed with lung adenocarcinoma each year in the United States, and 1 million people are diagnosed with lung adenocarcinoma each year worldwide.
Bayanan bayanan labarin ya nuna cewa yawan ayyukan direbobin oncogene na huhu adenocarcinoma ana sa ran zai zama sama da kashi 50%, kuma rashin daidaituwar kwayoyin halittar wadannan direbobi suna da mahimmanci ga ci gaban kansa. Ana ayyana waɗannan direbobi a matsayin “ayyukan” saboda ana iya juya su mara kyau ta hanyar kai hari ga kowane rukunin yanar gizo mara kyau a cikin kwayoyin halitta.
Dr. Mark G. Kris of the Memorial Sloan Kettering Cancer Center in New York et al. counted the frequency of carcinogenic drivers in patients with lung adenocarcinoma, and used this data to explore the proportion of patients who selected a certain targeted treatment together with overall survival . From 2009 to 2012, 14 centers in the huhu Cancer Mutation Alliance recruited patients with metastatic lung adenocarcinoma and tested tumors in patients who met specific criteria for 10 oncogene driver factors. The study was published in JAMA (2014; doi: 10.1001 / jama.2014.3741).
A yayin binciken, masu binciken sun gwada aƙalla kwayar halitta 1 akan ciwace-ciwacen marasa lafiya 1007, kuma sun gwada kwayoyin halitta 10 (cikakkun majinyatan kwayoyin halitta) akan ciwace-ciwacen marasa lafiya 733. Daga cikin marasa lafiya 733, 466 (64%) sun sami direban oncogene. 275 daga cikin 1007 marasa lafiya (28%) sun yi amfani da waɗannan sakamakon don zaɓar maganin da aka yi niyya ko shigar da gwaji na asibiti.
Matsakaicin rayuwa na marasa lafiya 260 waɗanda suka ɗauki direban oncogene kuma sun karɓi maganin miyagun ƙwayoyi da aka yi niyya shine shekaru 3.5; Matsakaicin rayuwa na marasa lafiya 318 waɗanda ke ɗaukar direban oncogene amma ba a yi niyya ba shine Shekaru 2.4; Tsakanin rayuwa na marasa lafiya 360 ba tare da direban da aka samu ba shine shekaru 2.1.
The researchers came to the conclusion that multiple genetic testing can help physicians choose a method of treating kwayar cutar huhu. Although patients with a certain target drug target driver gene will prolong survival after treatment, the design of this study cannot draw decisive conclusions about the difference in survival caused by oncogene driver.
Source: Lambun Lilac
